Characteristics and treatment outcomes among HIV-infected individuals in the Australian trial in acute hepatitis C

Clinical Infectious Diseases

Volumn 48, Issue 5, 2009, Pages 650-658

  Matthews, G V ^a   Hellard, M ^c,d   Haber, P ^b   Yeung, B ^a   Marks, P ^a   Baker, D ^b   McCaughan, G ^b   Sasadeusz, J ^d,e   White, P ^b   Rawlinson, W ^b   Lloyd, A ^b   Kaldor, J ^a   Dore, G J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; INTERFERON;

ADULT; AGE; ARTICLE; AUSTRALIA; CLINICAL TRIAL; CONCURRENT INFECTION; DEPRESSION; FEMALE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; SCREENING TEST; SEXUAL TRANSMISSION; SIDE EFFECT; TREATMENT OUTCOME; BLOOD; CLASSIFICATION; COHORT ANALYSIS; GENETICS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; PATHOLOGY; PROSPECTIVE STUDY; RISK FACTOR; VIRUS LOAD;

ADULT; AGE FACTORS; ANTIVIRAL AGENTS; AUSTRALIA; COHORT STUDIES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERONS; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 60549115339     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/596770     Document Type: Article

References (27)

1. Browne R, Asboe D, Gilleece Y, et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men: is sexual transmission feeding the increase? Sex Transm Infect 2004; 80:326-7.
2. Gambotti L, Batisse D, Colin-de-Verdiere N, et al. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill 2005; 10:115-7.
3. Ghosn J, Pierre-Francois S, Thibault V, et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med 2004; 5:303-6.
4. Gotz HM, van Doornum G, Niesters HG, den Hollander JG, Thio HB, de Zwart O. A cluster of acute hepatitis C virus infection among men who have sex with men - results from contact tracing and public health implications. AIDS 2005; 19:969-74.
5. Serpaggi J, Chaix ML, Batisse D, et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 2006; 20:233-40.
6. Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21:983-91.
7. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-9.
8. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-9.
9. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-50.
10. Luetkemeyer A, Hare CB, Stansell J, et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 41:31-6.
11. Vogel M, Nattermann J, Baumgarten A, et al. Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther 2006; 11:1097-101.
12. Vogel M, Bieniek B, Jessen H, et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat 2005; 12:207-11.
13. Dominguez S, Ghosn J, Valantin MA, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006; 20:1157-61.
14. Gilleece YC, Browne RE, Asboe D, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 2005; 40:41-6.
15. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345:1452-7.
16. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125:80-8.
17. Santantonio T, Fasano M, Sinisi E, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005; 42:329-33.
18. Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEPNET acute-HCV-II study. Hepatology 2006; 43:250-6.
19. Robotin MC, Copland J, Tallis G, et al. Surveillance for newly acquired hepatitis C in Australia. J Gastroenterol Hepatol 2004; 19:283-8.
20. Calleri G, Cariti G, Gaiottino F, et al. A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat 2007; 14:116-21.
21. Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006; 130:632-8.
22. Kamal SM, Moustafa KN, Chen J, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006; 43:923-31.
23. De Rosa FG, Bargiacchi O, Audagnotto S, et al. Twelve-week treatment of acute hepatitis C virus with pegylated interferon-α-2b in injection drug users. Clin Infect Dis 2007; 45:583-8.
24. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-52.
25. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 2004; 53:15-8.
26. Nunez M, Marino A, Miralles C, et al. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007; 45:439-44.
27. Crespo M, Esteban JI, Ribera E, et al. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV coinfected patients. AIDS 2007; 21:477-81.